Home
On-Demand
Industrie
FAQ
Home
On-Demand
Industrie
FAQ
Schlagwort
Tisotumab-Vedotin
Zervixkarzinom
Zervixkarzinom
Antiangionese
/
Antikörperwirkstoffkonjugat
/
Cemiplimab
/
Checkpoint-Inhibition
/
Dresdener Management
/
frühes CxCa
/
GOG 240
/
Induktionstherapie
/
innovaTV 301
/
KEYNOTE-826
/
KEYNOTE-A18
/
LACC-Studie
/
NACT
/
operative Therapie
/
pN0-Patientinnen
/
Radiochemotherapie
/
Senticol III
/
Sentinel +/- LNE
/
SHAPE
/
Tisotumab-Vedotin
Genitalkarzinome
Genitalkarzinome
Adenokarzinom
/
ALTALANTE-Studie
/
bevacizumab
/
BRCAm
/
CALLA-Studie
/
Cemiplimab
/
Cisplatin
/
Durvalumab
/
innovaTV 204-Studie
/
Lenvatinib
/
Paclitaxel
/
Pembrolizumab
/
RCTX
/
Tisotumab-Vedotin
/
Trastuzumab
